Fosun Pharma (02696.HK): Nalurinib monoclonal antibody biosimilar HLX18 for the treatment of various solid tumors in Phase 1 clinical trial approved by the US Food and Drug Administration.

Zhtng cijng APP xn, Fhng Hnln (02696.HK) fb gnggo, jnr, gngs zzh ynf de n w l yu dn kng shngw lis yo HLX18 (chngz kng PD-1 rnyun hu dn k mu kng tzh yo zhsh y) (HLX18) yngy duzhng sht t zhl de 1 q lnghun shyn shnqng (IND) hu migu shpn yo fgun l (FDA) pzh. Gngs n y tiojin jbi hu y migu kizhn gunx 1 q lnghun shyn.